CompletedNCT07053345
A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression
Medication studyAges 18–64South Korea
Understand this study
Who was this study for?
Listed age limits: 18 years to 64 years.
- Listed locations
- Goyang Si Gyeonggi Do and 5 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: June 9, 2025
- Recruitment status
- Completed
- Enrollment listed in the registry
- 47
- Sponsor
- Janssen Korea, Ltd., Korea
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- South Korea
- Age range
- From 18 Years to 64 Years
- Official registry ID
- NCT07053345
- Official title
Show the full official title
An Interventional, Open-label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of Esketamine Nasal Spray in Korean Participants With Treatment-Resistant Depression(TRD)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Goyang Si Gyeonggi Do · Iksan · Seoul
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Janssen Korea, Ltd., Korea.
Did this study involve medication?
Yes. The study involved medication, including Esketamine 56 mg and Esketamine 84 mg.
Who was this study for?
Listed age limits: 18 years to 64 years.
